Personalis, Inc. Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solutions for Use in Early Drug Discovery and Preclinical Studies
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of their Pharma Research Solutions, the latest expansion of the company’s portfolio of comprehensive genomics assays and analytics. These solutions, which leverage Personalis’ patented ACE Technology, are designed for use in early drug discovery and preclinical studies in oncology, but also other disease areas. These offerings complement Personalis’ comprehensive immunogenomics platform, ImmunoID NeXT™, which is currently used for clinical biomarker and companion diagnostic development in translational research and clinical trials by the company’s pharmaceutical partners.“Our Pharma Research Solutions provide our customers with access to a broad suite of both proprietary and standard assays from targeted DNA and RNA panels through to whole genome and whole exome and transcriptome services. Our expansive sample processing and sequencing capacity
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis (NASDAQ:PSNL) was given a new $11.00 price target on by analysts at Morgan Stanley.MarketBeat
- Personalis: A Growth Inflection Is Imminent, Hold [Seeking Alpha]Seeking Alpha
- Personalis to Participate in the Piper Sandler 37th Annual Healthcare ConferenceBusiness Wire
- Personalis (NASDAQ:PSNL) had its price target raised by analysts at Morgan Stanley from $5.00 to $9.00. They now have an "equal weight" rating on the stock.MarketBeat
- Personalis (NASDAQ:PSNL) had its price target raised by analysts at Guggenheim from $6.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
PSNL
Earnings
- 11/4/25 - Beat
PSNL
Sec Filings
- 11/28/25 - Form 8-K
- 11/28/25 - Form 424B5
- 11/28/25 - Form 4
- PSNL's page on the SEC website